AET01_AESI Table 1 (Default) Adverse Event of Special Interest Summary Table.
aet01_aesi.RdAET01_AESI Table 1 (Default) Adverse Event of Special Interest Summary Table.
Usage
aet01_aesi_main(
adam_db,
arm_var = "ACTARM",
aesi_vars = NULL,
grade_groups = NULL,
lbl_overall = NULL,
...
)
aet01_aesi_pre(adam_db, ...)
aet01_aesi_post(tlg, prune_0 = FALSE, ...)
aet01_aesiArguments
- adam_db
(
listofdata.frames) object containing theADaMdatasets- arm_var
(
string) variable used for column splitting- aesi_vars
(
character) the AESI variables to be included in the summary. Defaults toNA.- grade_groups
(
list) the grade groups to be displayed.- lbl_overall
(
string) label used for overall column, if set toNULLthe overall column is omitted- ...
not used.
- tlg
(
TableTree,Listingorggplot) object typically produced by amainfunction.- prune_0
(
flag) remove 0 count rows
Functions
aet01_aesi_main(): Main TLG functionaet01_aesi_pre(): Preprocessingaet01_aesi_post(): Postprocessing
Note
adam_dbobject must contain anadaetable with columns"AEOUT","AEACN","AECONTRT","AESER","AREL", and the column specified byarm_var.aesi_varsmay contain any/all of the following variables to display:"ALLRESWD","ALLRESDSM","ALLRESCONTRT","NOTRESWD","NOTRESDSM","NOTRESCONTRT","SERWD","SERDSM","SERCONTRT","RELWD","RELDSM","RELCONTRT","RELSER".-
aesi_varsvariable prefixes are defined as follows:"ALLRES"= "all non-fatal adverse events resolved""NOTRES"= "at least one unresolved or ongoing non-fatal adverse event""SER"= "serious adverse event""REL"= "related adverse event"
-
aesi_varsvariable suffixes are defined as follows:"WD"= "patients with study drug withdrawn""DSM"= "patients with dose modified/interrupted""CONTRT"= "patients with treatment received"
-
Several
aesi_varscan be added to the table at once:aesi_vars = "ALL"will include all possibleaesi_vars.Including
"ALL_XXX"inaesi_varswhereXXXis one of the prefixes listed above will include allaesi_varswith that prefix.
Examples
run(aet01_aesi, syn_data)
#> A: Drug X B: Placebo C: Combination
#> (N=134) (N=134) (N=132)
#> ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
#> Total number of patients with at least one AE 122 (91.0%) 123 (91.8%) 120 (90.9%)
#> Total number of AEs 609 622 703
#> Total number of patients with at least one AE by worst grade
#> Grade 1 7 (5.2%) 9 (6.7%) 4 (3.0%)
#> Grade 2 6 (4.5%) 10 (7.5%) 7 (5.3%)
#> Grade 3 18 (13.4%) 14 (10.4%) 16 (12.1%)
#> Grade 4 15 (11.2%) 20 (14.9%) 18 (13.6%)
#> Grade 5 (fatal outcome) 76 (56.7%) 70 (52.2%) 75 (56.8%)
#> Total number of patients with study drug withdrawn due to AE 27 (20.1%) 26 (19.4%) 30 (22.7%)
#> Total number of patients with dose modified/interrupted due to AE 66 (49.3%) 76 (56.7%) 74 (56.1%)
#> Total number of patients with treatment received for AE 98 (73.1%) 102 (76.1%) 103 (78.0%)
#> Total number of patients with all non-fatal AEs resolved 84 (62.7%) 92 (68.7%) 97 (73.5%)
#> Total number of patients with at least one unresolved or ongoing non-fatal AE 102 (76.1%) 110 (82.1%) 107 (81.1%)
#> Total number of patients with at least one serious AE 104 (77.6%) 101 (75.4%) 99 (75.0%)
#> Total number of patients with at least one related AE 105 (78.4%) 108 (80.6%) 109 (82.6%)